| Literature DB >> 26213479 |
Luis Bahamondes1, Maria Y Makuch1, Ilza Monteiro1, Victor Marin2, Richard Lynen3.
Abstract
BACKGROUND: Intrauterine contraceptives (IUCs), including the copper intrauterine device and the levonorgestrel-releasing intrauterine system (LNG-IUS), are among the reversible contraceptive methods with high effectiveness. However, use is low in many settings, including some Latin American countries, mainly due to the influences of myths, fears, and negative attitudes, not only of users and potential users, but also of different cadres of health care professionals. The purpose of this study was to assess the knowledge and attitudes of a group of Latin American obstetricians and gynecologists regarding IUCs.Entities:
Keywords: Latin America; attitudes; contraception; health care professionals; intrauterine contraceptives; knowledge; myths
Year: 2015 PMID: 26213479 PMCID: PMC4509537 DOI: 10.2147/IJWH.S84173
Source DB: PubMed Journal: Int J Womens Health ISSN: 1179-1411
Answers provided by obstetricians and gynecologists regarding failure rate of different contraceptive methods
| OBGYN characteristics
| ||||||
|---|---|---|---|---|---|---|
| Age (%)
| Sex (%)
| Working (%)
| ||||
| ≤49 years | ≥50 years | Female | Male | Public sector | Private/public sector | |
| What proportion of women use shorter acting methods (COC, patch, vaginal ring) up to 1 year? (n=168): | ||||||
| 50%–55% | 79.0 | 82.1 | 86.8 | 75.6 | 78.8 | 82.0 |
| 80%–85% | 21.0 | 17.9 | 13.2 | 24.4 | 21.2 | 18.0 |
| Failure rate of COC, patch, and vaginal ring given typical use (n=175): | ||||||
| 1%–2% | 32.5 | 34.4 | 38.0 | 30.0 | 32.7 | 34.5 |
| 4% | 16.2 | 24.1 | 11.1 | 27.1 | 17.3 | 21.0 |
| 8% | 31.1 | 29.3 | 28.6 | 31.4 | 32.7 | 28.4 |
| 10% | 20.3 | 12.1 | 22.2 | 11.4 | 17.3 | 16.0 |
| Failure rate per 100 women/year of LARC methods up to 1 year (n=194): | ||||||
| 0.3 | 95.6 | 80.8 | 88.9 | 88.8 | 83.3 | 90.3 |
| 5.0 | 0.0 | 5.8 | 0.0 | 5.7 | 2.8 | 3.2 |
| 13.0 | 4.4 | 9.6 | 11.1 | 3.8 | 11.1 | 4.8 |
| 22.0 | 0.0 | 3.8 | 0.0 | 3.8 | 2.8 | 1.7 |
Abbreviations: COC, combined oral contraceptive; LARC, long-acting reversible contraceptive.
Answers provided by obstetricians and gynecologists regarding some aspects of use of intrauterine contraceptives
| Age (%)
| Sex (%)
| Working (%)
| ||||
|---|---|---|---|---|---|---|
| ≤49 years | ≥50 years | Female | Male | Public sector | Private/public sector | |
| Do you offer IUC regularly to your patients? (n=202): | ||||||
| Never | 7.1 | 8.9 | 10.6 | 5.5 | 10.5 | 6.2 |
| Not to adolescents | 8.9 | 8.9 | 10.6 | 7.3 | 5.3 | 10.9 |
| Not to nulligravidas | 80.3 | 82.2 | 74.5 | 87.2 | 81.6 | 81.3 |
| Ever | 3.6 | 0.0 | 4.3 | 0.0 | 2.6 | 1.6 |
| Main barriers between OBGYN and patients to IUC use (n=205): | ||||||
| NSAIDs are mandatory before insertion for pain control | 10.1 | 9.5 | 7.3 | 11.4 | 10.9 | 8.9 |
| Could be inserted at any time within the menstrual cycle | 2.9 | 4.8 | 3.6 | 3.8 | 1.8 | 5.1 |
| TVUS is mandatory before insertion | 8.7 | 1.6 | 7.3 | 3.8 | 9.1 | 2.5 |
| Pain is more intense in nulligravidas | 5.8 | 1.6 | 5.5 | 2.5 | 0.0 | 6.3 |
| None of the preceding answers | 72.5 | 82.5 | 76.4 | 78.5 | 78.2 | 77.2 |
| LNG-IUS must be inserted in nulligravidas (n=203): | ||||||
| Never | 0.0 | 1.7 | 0.0 | 1.4 | 0.0 | 1.3 |
| Only if other contraceptive is not available | 7.0 | 5.0 | 5.0 | 6.8 | 3.6 | 7.6 |
| Ever | 92.9 | 90.0 | 93.4 | 90.5 | 96.3 | 88.6 |
| Could be inserted, but the woman must be advised that effectiveness is low | 0.0 | 3.3 | 1.7 | 1.4 | 0.0 | 1.3 |
| Ovarian cysts in LNG-IUS users must be treated with (n=205): | ||||||
| COC | 2.7 | 5.0 | 3.3 | 4.0 | 3.3 | 4.1 |
| Surgery if it does not disappear in 2 months | 2.7 | 0.0 | 0.0 | 2.7 | 1.6 | 1.4 |
| Removal of LNG-IUS | 1.4 | 0.0 | 1.7 | 0.0 | 0.0 | 1.4 |
| Spontaneously disappeared | 93.2 | 95.0 | 95.0 | 93.3 | 95.1 | 93.2 |
Abbreviations: COC, combined oral contraceptive; OBGYN, obstetricians and gynecologists; IUC, intrauterine contraceptive; NSAIDs, nonsteroidal anti-inflammatory drugs; TVUS, transvaginal ultrasound; LNG-IUS, levonorgestrel-releasing intrauterine system.